Title

One-Year Follow-Up after Percutaneous Coronary Intervention with Titanium-Nitride-Oxide-Coated Stents Versus Paclitaxel-Eluting Stents in Patients from Real-World Clinical Practice

Authors

Chuan-Chieh Liu;Jen-Yu Wang;I-Ping Yen;Chi-Jan Lai

Key Words

Major adverse cardiovascular event ; Paclitaxel-eluting stent ; Titanium-nitride-oxide-coated stent

PublicationName

Acta Cardiologica Sinica

Volume or Term/Year and Month of Publication

27卷2期(2011 / 06 / 01)

Page #

94 - 100

Content Language

英文

English Abstract

Background: Drug-eluting stents significantly decreased intimal hyperplasia in comparison with bare metal stents; however, safety issues have been reported by recent studies. In this study, titanium-nitride-oxide-coated stents, which exhibit less thrombogenicity, were compared to paclitaxel-eluting stents with respect to the rate of major adverse cardiovascular events (MACE).Methods: One hundred and fourteen patients [65 in titanium-nitride-oxide-coated (Titan(superscript ®)) stent group and 49 in paclitaxel-eluting (TAXUS(superscript ®)) stent group] were enrolled in a single teaching hospital in northern Taiwan between November 2005 and October 2008. Patients with acute coronary syndrome or chronic stable angina with a positive myocardial thallium scan were eligible for the study, and patients who underwent percutaneous coronary intervention (PCI) with either Titan stents or TAXUS stents were enrolled. We evaluated the MACE rate in the two groups during the first year after stent placement.Results: The MACE rates of the Titan and TAXUS groups were 10.8% (7/65) and 6.1% (3/49), respectively, but the difference was not statistically significant (p=0.3). In addition, the 12-month clinical outcomes were not statistically different between the groups. In a comparison of the risk factors of diabetes mellitus, acute myocardial infarction, hypertension, smoking, and dyslipidemia between the two groups, there was no significant difference in the rates of MACE.Conclusion: There was no difference in MACE or all-cause mortality at 12 months after stent implantation in patients who received the TAXUS or Titan stents.

Topic Category 醫藥衛生 > 內科